Literature DB >> 9625360

Serum leptin levels in children and adolescents with insulin-dependent diabetes mellitus in relation to metabolic control and body mass index.

W Kiess1, M Anil, W F Blum, P Englaro, A Juul, A Attanasio, J Dötsch, W Rascher.   

Abstract

The ob protein, termed leptin, is produced by adipocytes and is thought to act as an afferent satiety signal regulating weight through suppressing appetite and stimulating energy expenditure in humans and/or rodents. Insulin has been found to be a potent stimulator of leptin expression in rodents. It is unclear at present whether this insulin action is a direct or an indirect effect. To investigate whether leptin concentrations in children and adolescents with type 1 diabetes (IDDM) were related to metabolic status, body weight, body mass index and insulin treatment, we have measured leptin concentrations in serum from 13 newly diagnosed IDDM patients before the beginning of insulin treatment (8 girls, 5 boys, aged 4.7-17.5 years) and in 134 patients with IDDM during treatment (64 girls, 70 boys, aged 2.6-20.1 years) using a specific radioimmunoassay. The data from patients with diabetes were compared with normative data that were derived from a large cohort of healthy children and adolescents. Serum from children with newly diagnosed diabetes had significantly lower levels of leptin (mean 1.28+/-1.60 ng/ml, range 0.14-6.13 ng/ml) compared with healthy children (n=710) (mean 2.2 ng/ml, range 0.26-14.4ng/ml) and compared with insulin-treated children and adolescents (mean 5.18+/-5.48 ng/ml, range 0.26-29.77 ng/ml) (P<0.0001) even after adjustment for gender and body mass index (BMI). Serum leptin levels in patients with IDDM were significantly correlated with BMI (r=0.42, P<0.0001). Multiple regression analysis showed that age and BMI were significantly correlated with leptin levels, while duration of diabetes, mean HbA1c levels, insulin dose and plasma glucose, triglyceride and cholesterol levels were not. Females had higher serum leptin concentrations than males even when adjusted for BMI (P<0.0001). Surprisingly and most importantly, leptin levels in insulin-treated young adult (Tanner stage 5) patients were significantly higher than values found in the healthy nondiabetic reference population when adjusted for sex, Tanner stage and BMI. These findings suggest that leptin levels in IDDM patients show a similar dependency on adipose tissue and age as in healthy, normal children. The data provide evidence that insulin may be of importance as a regulator of serum leptin levels in vivo not only in rodents but also in humans. It is hypothesized that the elevated BMI-adjusted leptin levels in adolescents with IDDM could indicate either that these patients may be oversubstituted by the intensified insulin therapy that they are receiving or that their body composition and body fat content may differ from that of healthy adolescents in the sense that they have a relative increase in fat mass.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9625360     DOI: 10.1530/eje.0.1380501

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  14 in total

1.  Pathophysiological role of enhanced bone marrow adipogenesis in diabetic complications.

Authors:  Meghan A Piccinin; Zia A Khan
Journal:  Adipocyte       Date:  2014-12-10       Impact factor: 4.534

2.  Absence of leptin triggers type 1 diabetes.

Authors:  Bettina Mittendorfer; Samuel Klein
Journal:  Nat Med       Date:  2014-07       Impact factor: 53.440

Review 3.  Skeletal growth and bone mineral acquisition in type 1 diabetic children; abnormalities of the GH/IGF-1 axis.

Authors:  Manish Raisingani; Brar Preneet; Brenda Kohn; Shoshana Yakar
Journal:  Growth Horm IGF Res       Date:  2017-04-28       Impact factor: 2.372

4.  Serum leptin, adiponectin and tumor necrosis factor-α in hyperlipidemic rats with/without concomitant diabetes mellitus.

Authors:  Angeliki Margoni; Despoina N Perrea; Ioannis Vlachos; Georgia Prokopaki; Alkistis Pantopoulou; Lambros Fotis; Maria Kostaki; Athanasios G Papavassiliou
Journal:  Mol Med       Date:  2010-09-08       Impact factor: 6.354

Review 5.  Adiponectin and leptin: potential tools in the differential diagnosis of pediatric diabetes?

Authors:  Milagros Gloria Huerta
Journal:  Rev Endocr Metab Disord       Date:  2006-09       Impact factor: 6.514

Review 6.  Diabetes and Bone Marrow Adiposity.

Authors:  Tiffany Y Kim; Anne L Schafer
Journal:  Curr Osteoporos Rep       Date:  2016-12       Impact factor: 5.096

7.  Leptin treatment prevents type I diabetic marrow adiposity but not bone loss in mice.

Authors:  Katherine J Motyl; Laura R McCabe
Journal:  J Cell Physiol       Date:  2009-02       Impact factor: 6.384

8.  Leptin as an adjunct of insulin therapy in insulin-deficient diabetes.

Authors:  F Miyanaga; Y Ogawa; K Ebihara; S Hidaka; T Tanaka; S Hayashi; H Masuzaki; K Nakao
Journal:  Diabetologia       Date:  2003-08-20       Impact factor: 10.122

9.  Beneficial effects of leptin on glycaemic and lipid control in a mouse model of type 2 diabetes with increased adiposity induced by streptozotocin and a high-fat diet.

Authors:  T Kusakabe; H Tanioka; K Ebihara; M Hirata; L Miyamoto; F Miyanaga; H Hige; D Aotani; T Fujisawa; H Masuzaki; K Hosoda; K Nakao
Journal:  Diabetologia       Date:  2009-01-24       Impact factor: 10.122

10.  Type I diabetic bone phenotype is location but not gender dependent.

Authors:  Lindsay M Martin; Laura R McCabe
Journal:  Histochem Cell Biol       Date:  2007-07-03       Impact factor: 4.304

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.